Clinical Trials
90 trialsComparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
ARCADIAN
University of Oxford
LUNG-05
University of Illinois at Chicago
COMET
Intergroupe Francophone de Cancerologie Thoracique
BRIDGE
Mario Negri Institute for Pharmacological Research
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
City of Hope Medical Center
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Rochester
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
NORA
Spanish Lung Cancer Group
Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer
University of Nebraska
DURATION
AIO-Studien-gGmbH
NVB Metro
Assistance Publique Hopitaux De Marseille
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
NARLAL
Odense University Hospital
VinMetAtezo
University Hospital, Brest
VIM
Wales Cancer Trials Unit
Toco-Pulm
Vejle Hospital
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
Shanghai Pulmonary Hospital, Shanghai, China
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
EPIC
University of Turin, Italy
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
VINORELBINA
International Group of Endovascular Oncology
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
Samsung Medical Center
CTC-TCM-FZ
Shanghai University of Traditional Chinese Medicine
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
Thoraxklinik-Heidelberg gGmbH
ONC-MANILA12
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
VIVOS
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
RCTACSCNSCLC
Shenzhen People's Hospital
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Memorial Sloan Kettering Cancer Center
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
Medical University of South Carolina
RACCOSA
University Hospital, Limoges
HighTySy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
Yonsei University
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Xinqiao Hospital of Chongqing
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
Tianjin Medical University Cancer Institute and Hospital
Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer
Hellenic Oncology Research Group
Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Chemoradiotherapy of NSCLC Stage IIIB
Intergroupe Francophone de Cancerologie Thoracique
VENUS-1
Aktion Bronchialkarzinom e.V.
DISTAL-2
National Cancer Institute, Naples
G-Step
National Cancer Institute, Naples